News & Events
In the Media
Thursday, January 08, 2026
There has long been a paradigm in oncology: the search for specific target molecules on tumor cells in order to eliminate them in a targeted manner. The biotech company Vidac Pharma is now pursuing a radically different path. Instead of flipping a...
In the Media 2025
Sunday, October 26, 2025
The pharmaceutical market is enormous - and continues to grow. Market research institute Evaluate forecasts an increase to around USD 1.7 trillion by 2030, representing an annual growth rate of 7.7%. Oncology promises the highest sales, at around...
Tuesday, July 29, 2025
Current research approaches to the Warburg effect focus on depriving cancer cells of nutrients on the one hand and oxidative stress on the other, which makes other therapies more effective. The biotech company Vidac Pharma is fully committed to...
Monday, May 19, 2025
One company that could grow particularly dynamically due to its unique position is Vidac Pharma. Vidac's business model is based on a unique approach: reversing the Warburg effect. Cancer cells prefer to use glucose fermentation (Warburg effect)...
Sunday, May 11, 2025
Vidac Pharma is positioning itself as a pioneer in cancer research with two promising drug candidates, VDA-1275 and VDA-1102. Both aim to reverse the disturbed metabolism of tumor cells. This approach represents an entirely new treatment method....
Wednesday, April 30, 2025
Vidac Pharma's stock currently offers very exciting catch-up potential. The share price development is clearly lagging behind the positive news flow. Analysts even believe that the share price could multiply. The key price drivers are the two...
Sunday, April 27, 2025
The two most important products are an ointment (VDA-1102) for an early form of skin cancer and cutaneous T-cell lymphoma, and the active ingredient VDA-1275, which targets solid tumors and has shown strong synergistic effects with chemotherapeutic...
Thursday, April 03, 2025
At Vidac Pharma, positive news flow and share price performance remain disconnected. While the stock is now trading at just EUR 0.53 after starting the year at EUR 0.81, the Company is consistently working on a new class of cancer treatments. This...
Monday, March 24, 2025
In contrast to the Bayer Group, the biopharmaceutical company, led by Max Herzberg, one of the founding fathers of the Israeli life sciences industry, is doing extremely well. The Company's approach is revolutionary. Vidac Pharma is developing...
Thursday, March 20, 2025
Vidac Pharma has attracted attention at the First Pediatric Brain Tumor Research Meeting in Jerusalem. Dr. Max Herzberg, CEO of the Company, presented data on the drug candidate VDA-1102, which successfully penetrated the blood-brain barrier in a...
Monday, March 10, 2025
The biopharmaceutical company Vidac Pharma is inspiring new confidence among investors and millions of patients undergoing oncology treatment. As a clinical-stage company, it is developing therapies that target cancer cells by reversing their...
Wednesday, March 05, 2025
Vidac Pharma is one of the biotech shooting stars on the German stock market, with a share price increase of over 120% in the last 6 months. The Israeli company has a long history and is a pioneer in biopharmaceutical research. At the center of its...
Wednesday, February 19, 2025
Vidac Pharma is positioning itself as an innovator with two highly interesting projects: The systemic agent VDA-1275 shows synergistic effects with chemotherapies in preclinical studies. In colorectal cancer models, the combination with Cisplatin...
Friday, February 14, 2025
Will Vidac Pharma continue its rally soon? There is a good chance that the biotech highflyer of the second half of 2024 has ended its consolidation. The Company aims to revolutionize cancer treatment and has attracted much attention within the...
Tuesday, February 04, 2025
Cancer ranks as the second leading cause of death in Germany, accounting for 22% of all deaths. According to Destatis, people between the ages of 40 and 74 are particularly affected by the insidious disease, with more men than women impacted (54%...
Thursday, January 30, 2025
Biotechnological research in 2025 will be characterised by several key trends, technologies and social challenges. By utilising knowledge and money, mankind hopes to make progress in medicine, agriculture, the environment and industry. Whether it...
Wednesday, January 22, 2025
The margins for manufacturers of cancer drugs are often in the high double-digit percentage range. It is no wonder that companies are focusing on the fight against cancer. Developing a medication that reliably defeats the disease could result in a...
Tuesday, January 14, 2025
Since the end of May of the past stock market year 2024, shares of the biopharmaceutical oncology company have risen by approximately 275% to EUR 0.74. According to the analyst firm Sphene Capital, the price target, which was already set around six...
Monday, January 06, 2025
One of the top performers in the last 6 months was the biotech small-cap Vidac Pharma, with a price increase of over 150%. Founded in 2012, the Company is led by Prof Max Herzberg, one of the founding fathers of the Israeli life sciences industry....
In the Media 2024
Monday, December 23, 2024
Morbid obesity can lead to an increase in 13 different types of cancer. According to the WHO's International Agency for Research on Cancer, these include pancreatic cancer, thyroid cancer and breast cancer (after menopause). However, the therapies...
Tuesday, December 10, 2024
There have already been two attempts, but the story continues! Evotec speculators were confronted with a rumor mill and a takeover bid in November. This is what happens when a stock plummets and languishes for a long time. The management wisely...
Tuesday, December 03, 2024
Vidac Pharma celebrated a significant milestone on September 19: The US Patent and Trademark Office (USPTO) has granted the biopharmaceutical company a broad patent that protects the unique mechanisms of its cancer therapies. This protection...
Thursday, November 21, 2024
An impressive report done by top analyst Herr Peter Thilo Hasler for Sphene Capital GmbH on Vidac Pharma shows what we already knew: our company is in the right direction and indeed the "buy" recommendation of this highly professional Analyst is a...
Monday, November 18, 2024
Vidac Pharma is one of the biotech shooting stars on the German stock market, with its share price having risen by over 230% in the last six months. The Company is now receiving a reinvestment of EUR 600,000 from shareholders to advance the...
Thursday, November 07, 2024
The British biotech company Vidac Pharma (ISIN GB00BM9XQ619) has reached an important milestone in the development of innovative cancer therapies. The US Patent Office has granted the Company a groundbreaking patent for a completely new therapeutic...
Sunday, October 27, 2024
This is slowly turning into a long-term story. We have reported on Vidac Pharma plc several times in recent weeks . There has been tremendous interest in the stock recently, and even with a premium of 300% at the peak, there are now further...
Monday, October 14, 2024
Vidac Pharma's stock has been one of the positive surprises of the past few months. Driven by strong newsflow, the share price of the cancer-focused company has more than doubled since its low at the end of May at under EUR 0.18. The current...
Saturday, October 05, 2024
Vidac Pharma (ISIN: GB00BM9XQ619), a clinical-stage biopharmaceutical company specializing in the development of a novel class of cancer treatments, has been awarded a patent by the United States Patent and Trademark Office (USPTO). This patent...
Sunday, September 29, 2024
The biopharmaceutical oncology company Vidac Pharma (WKN: A3DTUQ | ISIN: GB00BM9XQ619 | Ticker Symbol: T9G) has reported several successes this year. At the end of March 2024, the company received approval from the Japanese Patent Office for its...
Monday, September 16, 2024
Those interested in investing in promising biotech small-caps should keep Vidac Pharma on the radar. Despite its manageable size, the Company is already in the clinical development phase. The best-known product, VDA-1275, is the focus of interest...
Wednesday, September 11, 2024
Vidac Pharma shares have gained over 23% in the past four weeks. Driven by strong study data from the biotech company focused on fighting cancer, analysts even see the potential for multiplication. Such euphoria has been absent at Bayer for some...
Wednesday, September 04, 2024
Vidac Pharma, a listed company in the clinical development phase, offers an exciting and promising prospect. Vidac Pharma's latest product, VDA-1275, is at the center of interest following a technical report. This innovative drug candidate for the...
Thursday, August 29, 2024
The new technology being developed by Vidac Pharma, a company founded in 2012 and led by Prof. Max Herzberg, one of the founding fathers of the Israeli life sciences industry, is groundbreaking. Vidac Pharma is researching drugs designed to help...
Wednesday, August 07, 2024
Among the biotech small-cap stocks, Vidac Pharma has recently made headlines. The British-Israeli company has recently published promising results of its studies with the promising compound VDA-1275 in several mouse and human cellular organoid...
Friday, August 02, 2024
A mega rally could start here, at least according to analysts who analyzed the recently published results of tests with next-generation drug candidates in human and murine tumour models. According to the analysis, Sphene Capital sees a price target...
Friday, July 05, 2024
With around 20 million cancer diagnoses worldwide each year, innovative therapeutic approaches are urgently needed. Companies such as Vidac Pharma are currently developing new ways of treating cancer that could lead to a groundbreaking...
Saturday, June 22, 2024
We have reported several times on Vidac Pharma plc in recent weeks. The interest in the share is enormous for a penny stock, with over 200,000 shares changing hands at times. The Company has just announced that the US Patent and Trademark Office...
Thursday, June 13, 2024
The biopharmaceutical company Vidac Pharma, which specializes in developing innovative cancer treatments, has recently achieved a significant milestone. On June 3, the Company was awarded a key patent for its group of molecules by the US Patent and...
Wednesday, May 29, 2024
FinanzNachrichten provides financial news and updates specifically related to Vidac Pharma Holdings PLC. It covers the company's stock performance, recent financial news, market analysis, and any significant corporate announcements. The page serves...
Wednesday, May 29, 2024
Vidac Pharma has not yet broken out of its sideways movement, but this is likely only a matter of time. The London-based biotech company is making good progress in cancer research and has been traded as a takeover candidate, especially since...
Thursday, May 09, 2024
There is hope on the horizon for biotech investors, according to news | financial, even if a rally in the Nasdaq Biotech Index late last year did not persist in 2024. Tough refinancing conditions have been holding the market back, according to the...
Monday, April 29, 2024
Oncology is on the brink of a golden era. Driven by an increase in cancer cases and impressive scientific advances, including gene and immunotherapies, a billion-dollar market with immense growth prospects is emerging. The increasing demand for...
Monday, April 22, 2024
UK and Israel-based Vidac Pharma plc (STU: T9G, WKN: A3DTUQ, ISIN: GB00BM9XQ619) is another clinical-stage biopharmaceutical company developing first-in-class oncology and oncodermatology therapies. Its breakthrough new technology, which corrects a...
Wednesday, April 17, 2024
The biopharmaceutical company Vidac Pharma (WKN: A3DTUQ | ISIN: GB00BM9XQ619 | Ticker symbol: T9G), which is based in Israel and the UK, received notification of approval for its drug candidate VDA-1275 from the Japanese Patent Office at the end of...
Monday, April 08, 2024
Since the onset of the COVID-19 pandemic, there has been little movement in the biotech sector. However, after a challenging year in 2023, the sector was at least able to start the new year on a solid footing. The surprising takeover of MorphoSys...